108. TNF receptor-associated periodic syndrome
4 clinical trials, 7 drugs (DrugBank: 1 drug), 1 drug target gene, 42 drug target pathways
Searched query = "TNF receptor-associated periodic syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-020061-24-IT (EUCTR) | 20/09/2010 | 05/07/2010 | An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - ND | An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) - ND | Active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS) MedDRA version: 12.1;Level: LLT;Classification code 10034533;Term: Periodic fever | Product Name: canakinumab Product Code: ACZ885D INN or Proposed INN: Canakinumab | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 50 | Ireland;United Kingdom;Italy |